The Zhitong Finance App learned that Federal Pharmaceuticals (03933) rose more than 7% at the end of the session. As of press release, it had risen 6.67% to HK$10.2, with a turnover of HK$70373,700.

According to the news, recently, Shanghai Sunshine Pharmaceutical Procurement Network announced the results of the National Centralized Drug Procurement (Insulin Special Project) selection results. Xiangcai Securities pointed out that the insulin market has continued to recover since the first round of national collection. We believe that the market is overly pessimistic about this category, ignoring the core barriers inherent in the industrial production of insulin and the medical service value behind such drugs. This time, prices have remained relatively stable and the standard period has been extended, and we judge that the overall market is expected to bottom up. It is recommended to focus on potential value restoration investment opportunities for leading insulin companies.

According to reports, in the continuation of the current special national insulin procurement, all six insulin products declared by Federal Pharmaceuticals will be selected as Class A. According to the company, the prices of the products to be selected by the company have been lowered moderately compared to the sixth batch of centralized procurement of national drugs (insulin special), but the procurement base volume has increased significantly by 52.5%. At the same time, all of the company's Class A selected products will also receive the remaining distribution amount. According to Guojin Securities, the six federal pharmaceuticals' product line has been selected as Class A, and it is expected that this collection will be used to accelerate the volume of sales.